Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7654562

NCCCn1cc(-c2nc3cc4ccccc4cc3n(Cc3ccccc3)c2=O)c2ccccc21.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 14/20 0.45
CFTR P13569 4/20 0.41
PIM1 P11309 1/20 0.40
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HBB P68871 1/20 0.39
TPSAB1 Q15661 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7806936 0.91 CFTR (0.49) CAMK2DCFTRUSP2ALDH1A1CYP1A2
Trifluoroacetic Acid SCHEMBL7658458 0.87 CAMK2D (0.42) CAMK2DPIM1USP2ALDH1A1CYP1A2
Acetic Acid SCHEMBL7658116 0.84 CAMK2D (0.49) CAMK2DPIM1USP2ALDH1A1CYP1A2
Trifluoroacetic Acid SCHEMBL7815291 0.83 CAMK2D (0.46) CAMK2DPIM1USP2ALDH1A1CYP1A2
Trifluoroacetic Acid SCHEMBL7817667 0.82 CAMK2D (0.44) CAMK2DPIM1
Trifluoroacetic Acid SCHEMBL8516825 0.82 CA12 (0.40) CAMK2DPIM1USP2ALDH1A1CYP1A2
Trifluoroacetic Acid SCHEMBL7818314 0.81 CAMK2D (0.48) CAMK2DPIM1ALDH1A1
Trifluoroacetic Acid SCHEMBL7815071 0.80 ALDH1A1 (0.49) CAMK2DPIM1USP2ALDH1A1CYP1A2
Trifluoroacetic Acid SCHEMBL7814735 0.80 PDE4B (0.44) CAMK2DCFTRPIM1USP2ALDH1A1
SCHEMBL7663803 0.80 CAMK2D (0.52) CAMK2DCFTRUSP2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US claimed
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed